logo

For the Inventor, By the Inventor

San Francisco, CA, United States of America

Silver Creek Pharmaceuticals, Inc.


USPTO Granted Patents = 10


Forward Citations = 26

Loading Chart...
Loading Chart...

15 inventors (with patents filed for the assignee):

goldMedal Matthew D Onsum (10 out of 17 patents)

silverMedal Laura D J Antipov (5 out of 5 patents)

bronzeMedal Shawdee Eshghi (5 out of 5 patents)

4.  Kristopher M Kuchenbecker (5 out of 5 patents)

5.  Bjorn L Millard (5 out of 5 patents)

6.  Andrea D Nickerson (5 out of 5 patents)

7.  Timothy R Stowe (5 out of 6 patents)

8.  Thomas Joseph Wickham (5 out of 15 patents)

9.  Brian Harms (5 out of 13 patents)

10.  Birgit Schoeberl (5 out of 18 patents)

11.  Bryan Linggi (5 out of 11 patents)

12.  Byron DeLaBarre (5 out of 9 patents)

13.  Yan Zhang (5 out of 14 patents)

14.  Ulrik Bjerl Nielsen (5 out of 26 patents)

15.  Shaun M Lippow (3 out of 13 patents)


10 patents:

1. 12122819 - Method of treating skin tissue damage by topically administering a bi-specific protein comprising a human insulin-like growth factor variant and a human annexin A5 variant (2024-10-22),
2. 11879002 - Bi-specific therapeutic proteins, in vivo methods of use thereof and encoding nucleic acids thereof (2024-01-23),
3. 11814443 - Bi-specific fusion proteins (2023-11-14),
4. 11673970 - Bi-specific fusion proteins (2023-06-13),
5. 11155593 - Method of inhibiting apoptosis or promoting cell survival by providing a bi-specific protein comprising insulin-like growth factor IGF-1 and Annexin A5 (2021-10-26),
6. 10988547 - Bi-specific fusion proteins (2021-04-27),
7. 10858450 - Bi-specific fusion proteins (2020-12-08),
8. 10633425 - Method of protecting tissue from damage by administering a bi-specific therapeutic protein comprising insulin-like growth factor 1 (IGF-1) and Annexin A5 (2020-04-28),
9. 10407512 - Bi-specific fusion proteins (2019-09-10),
10. 10040840 - Bi-specific annexin A5/IGF-1 proteins and methods of use thereof to promote regeneration and survival of tissue (2018-08-07),
Company Overview
Silver Creek Pharmaceuticals, Inc. is a biotechnology company based in San Francisco, California, focused on developing innovative therapies for patients with unmet medical needs. The organization specializes in the research and development of novel treatments, particularly in the fields of neurology and rare diseases. By leveraging advanced scientific methodologies and a commitment to patient-centric solutions, Silver Creek aims to transform the landscape of therapeutic options and improve health outcomes for diverse patient populations.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

Silver Creek Pharmaceuticals, Inc. USPTO Patent Assignee Logo
10 Patents

#448 in San Francisco, CA

#7,118 in California

#29,882 in US

#56,092 in the World

San Francisco, CA (US)
San Francisco, CA, United States of America

Silver Creek Pharmaceuticals, Inc.

Forward Citations = 26

15 inventors:

goldMedal Matthew D Onsum (10 out of 17 patents)

silverMedal Laura D J Antipov (5 out of 5 patents)

bronzeMedal Shawdee Eshghi (5 out of 5 patents)

4.  Kristopher M Kuchenbecker (5 out of 5 patents)

5.  Bjorn L Millard (5 out of 5 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Silver Creek Pharmaceuticals, Inc.. Retrieved from https://idiyas.com/company/silver-creek-pharmaceuticals

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…